Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net

Abstract excerpt

Acute myeloid leukemia (AML) has a median age at diagnosis of 68 years, and many patients are deemed ineligible for intensive chemotherapy or allogeneic stem cell transplantation, resulting in a generally poor prognosis [ 1 ]. The pivotal VIALE-A randomized trial showed that Azacitidine (AZA) at 75 mg/m²/day for 7 days every 28 days, combined with once-daily continuous Venetoclax (VEN) at 400 mg for 28 days,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Hematopoietic Stem Cell Transplantation
• Share to Vascular Tumors and Angiosarcomas